share_log

Bristol-Myers Squibb | DEFA14A: Others

Bristol-Myers Squibb | DEFA14A: Others

施貴寶 | DEFA14A：其他
SEC announcement ·  03/29 10:39
牛牛AI助理已提取核心訊息
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy solicitation. The company has confirmed that no filing fee is required for this submission. The nature of the additional materials has not been specified in the announcement.
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy solicitation. The company has confirmed that no filing fee is required for this submission. The nature of the additional materials has not been specified in the announcement.
領先的製藥公司百時美施貴寶已向美國證券交易委員會（SEC）提交了明確的補充材料，作爲其委託書的一部分。根據1934年《證券交易法》第14（a）條，該文件表明，這些材料旨在與公司股東就代理招標進行進一步溝通。該公司已確認本次提交不需要任何申請費。公告中未具體說明額外材料的性質。
領先的製藥公司百時美施貴寶已向美國證券交易委員會（SEC）提交了明確的補充材料，作爲其委託書的一部分。根據1934年《證券交易法》第14（a）條，該文件表明，這些材料旨在與公司股東就代理招標進行進一步溝通。該公司已確認本次提交不需要任何申請費。公告中未具體說明額外材料的性質。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。